{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:16:12Z","timestamp":1760955372203},"reference-count":28,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2013,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Anthrax, caused by\n            <jats:named-content content-type=\"genus-species\">Bacillus anthracis<\/jats:named-content>\n            , is primarily a zoonotic disease. Being a public health problem also in several developing countries, its early diagnosis is very important in human cases. In this study, we describe the use of an indirect enzyme-linked immunosorbent assay (ELISA) for detection of anti-lethal factor (anti-LF) IgG in human serum samples. A panel of 203 human serum samples consisting of 50 samples from patients with confirmed cutaneous anthrax, 93 samples from healthy controls from areas of India where anthrax is nonendemic, 44 samples from controls from an area of India where anthrax is endemic, and 16 patients with a disease confirmed not to be anthrax were evaluated with an anti-LF ELISA. The combined mean anti-LF ELISA titer for the three control groups was 0.136 ELISA unit (EU), with a 95% confidence interval (CI) of 0.120 to 0.151 EU. The observed sensitivity and specificity of the ELISA were 100% (95% CI, 92.89 to 100%) and 97.39% (95% CI, 93.44 to 99.28%), respectively, at a cutoff value of 0.375 EU, as decided by receiver operating characteristic (ROC) curve analysis. The likelihood ratio was found to be 49.98. The positive predictive value (PPV), negative predictive value (NPV), efficiency, and Youden's index (\n            <jats:italic>J<\/jats:italic>\n            ) for reliability of the assay were 92.5%, 100%, 98.02%, and 0.97, respectively. The false-positive predictive rate and false-negative predictive rate of the assay were 2.61% and 0%. The assay could be a very useful tool for early diagnosis of cutaneous anthrax cases, as antibodies against LF appear much earlier than those against other anthrax toxins in human serum samples.\n          <\/jats:p>","DOI":"10.1128\/cvi.00598-12","type":"journal-article","created":{"date-parts":[[2012,12,27]],"date-time":"2012-12-27T01:34:28Z","timestamp":1356572068000},"page":"282-286","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":15,"title":["Serodiagnosis of Human Cutaneous Anthrax in India Using an Indirect Anti-Lethal Factor IgG Enzyme-Linked Immunosorbent Assay"],"prefix":"10.1128","volume":"20","author":[{"given":"N.","family":"Ghosh","sequence":"first","affiliation":[{"name":"Biotechnology Division, Defence Research &amp; Development Establishment, Gwalior, Madhya Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Tomar","sequence":"additional","affiliation":[{"name":"Biotechnology Division, Defence Research &amp; Development Establishment, Gwalior, Madhya Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Lukka","sequence":"additional","affiliation":[{"name":"Dr. Pinnamaneni Siddhartha Institute of Medical Sciences, Gannavaram, Andhra Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. K.","family":"Goel","sequence":"additional","affiliation":[{"name":"Biotechnology Division, Defence Research &amp; Development Establishment, Gwalior, Madhya Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909093411107"},{"key":"e_1_3_2_3_2","volume-title":"Maxey-Rosenau-Last public health and preventive medicine","author":"Shadomy SV","year":"2008","unstructured":"ShadomySV RosensteinNE. 2008. Anthrax, p 427\u2013430. In WallaceRB (ed), Maxey-Rosenau-Last public health and preventive medicine, 15th ed. McGraw-Hill Co., New York, NY.","edition":"15"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/MD.0b013e3181c202fa","article-title":"Three related cases of cutaneous anthrax in France: clinical and laboratory aspects","volume":"88","author":"Cinquetti G","year":"2009","unstructured":"CinquettiG BanalF DupuyAL GiraultPY CoudercA GuyotP AlauzetC OddouxO RagotC PuyhardyJM GraffinB VeranY. 2009. Three related cases of cutaneous anthrax in France: clinical and laboratory aspects. Medicine (Baltimore) 88:371\u2013375.","journal-title":"Medicine (Baltimore)"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0140-6736(05)64718-6","article-title":"Anthrax in southern India","volume":"348","author":"Lalitha MK","year":"1996","unstructured":"LalithaMK KumarA. 1996. Anthrax in southern India. Lancet 348:553\u2013554.","journal-title":"Lancet"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev.cellbio.19.111301.140655","article-title":"Anthrax toxin","volume":"19","author":"Collier RJ","year":"2003","unstructured":"CollierRJ YoungJA. 2003. Anthrax toxin. Annu. Rev. Cell Dev. Biol. 19:45\u201370.","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.280.5364.734"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.79.10.3162"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1042\/BJ20061891","article-title":"Manipulation of host signalling pathways by anthrax toxins","volume":"402","author":"Turk BE","year":"2007","unstructured":"TurkBE. 2007. Manipulation of host signalling pathways by anthrax toxins. Biochem. J. 402:405\u2013417.","journal-title":"Biochem. J."},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"8410","DOI":"10.1016\/j.vaccine.2007.09.063","article-title":"Catalytically inactive anthrax toxin(s) are potential prophylactic agents","volume":"25","author":"Gupta M","year":"2007","unstructured":"GuptaM AlamS BhatnagarR. 2007. Catalytically inactive anthrax toxin(s) are potential prophylactic agents. Vaccine 25:8410\u20138419.","journal-title":"Vaccine"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(01)00234-1"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00154-12"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/infdis\/jir543","article-title":"Lethal factor toxemia and anti-protective antigen antibody activity in naturally acquired cutaneous anthrax","volume":"204","author":"Boyer AE","year":"2011","unstructured":"BoyerAE QuinnCP BeesleyCA Gallegos-CandelaM MarstonCK CroninLX LinsRC StoddardRA LiH SchifferJ HossainMJ ChakrabortyA RahmanM LubySP ShiehWJ ZakiS BarrJR HoffmasterAR. 2011. Lethal factor toxemia and anti-protective antigen antibody activity in naturally acquired cutaneous anthrax. J. Infect. Dis. 204:1321\u20131327.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/423937"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1128\/IAI.69.7.4509-4515.2001","article-title":"Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein","volume":"69","author":"Price BM","year":"2001","unstructured":"PriceBM LinerAL ParkS LepplaSH MateczunA GallowayDR. 2001. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect. Immun. 69:4509\u20134515.","journal-title":"Infect. Immun."},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.micpath.2004.10.007","article-title":"Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain","volume":"38","author":"Flick-Smith HC","year":"2005","unstructured":"Flick-SmithHC WatersEL WalkerNJ MillerJ StaggAJ GreenM WilliamsonED. 2005. Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain. Microb. Pathog. 38:33\u201340.","journal-title":"Microb. Pathog."},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1574-695X.2011.00800.x","article-title":"The early humoral immune response to Bacillus anthracis toxins in patients infected with cutaneous anthrax","volume":"62","author":"Brenneman KE","year":"2011","unstructured":"BrennemanKE DoganayM AkmalA GoldmanS GallowayDR MateczunAJ CrossAS BaillieLW. 2011. The early humoral immune response to Bacillus anthracis toxins in patients infected with cutaneous anthrax. FEMS Immunol. Med. Microbiol. 62:164\u2013172.","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1258\/td.2012.110454","article-title":"Human-animal anthrax outbreak in the Luangwa valley of Zambia in 2011","volume":"42","author":"Hang'ombe MB","year":"2012","unstructured":"Hang'ombeMB MwansaJC MuwowoS MulengaP KapinaM MusengaE SquarreD MataaL ThomasSY OgawaH SawaH HigashiH. 2012. Human-animal anthrax outbreak in the Luangwa valley of Zambia in 2011. Trop. Doct. 42:136\u2013139.","journal-title":"Trop. Doct."},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3855\/jidc.551","article-title":"Characteristics of cutaneous anthrax in Turkey","volume":"3","author":"Baykam N","year":"2009","unstructured":"BaykamN ErgonulO UluA ErenS CelikbasA ErogluM DokuzoguzB. 2009. Characteristics of cutaneous anthrax in Turkey. J. Infect. Dev. Countr. 3:599\u2013603.","journal-title":"J. Infect. Dev. Countr."},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4103\/0970-0218.62573","article-title":"Anthrax: public health risk in India and socio-environmental determinants","volume":"35","author":"Patil RR","year":"2010","unstructured":"PatilRR. 2010. Anthrax: public health risk in India and socio-environmental determinants. Indian J. Community Med. 35:189\u2013190.","journal-title":"Indian J. Community Med."},{"key":"e_1_3_2_21_2","first-page":"240","article-title":"Human anthrax in India: urgent need for effective prevention","volume":"32","author":"Kumar A","year":"2000","unstructured":"KumarA KanungoR BhattacharyaS BadrinathS DuttaTK SwaminathanRP. 2000. Human anthrax in India: urgent need for effective prevention. J. Commun. Dis. 32:240\u2013246.","journal-title":"J. Commun. Dis."},{"key":"e_1_3_2_22_2","volume-title":"Prism 5 statistics guide 2007","author":"Motulsky HJ","year":"2007","unstructured":"MotulskyHJ. 2007. Prism 5 statistics guide 2007. GraphPad Software Inc., San Diego CA."},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1161\/CIRCULATIONAHA.105.594929","article-title":"Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models","volume":"115","author":"Zou KH","year":"2007","unstructured":"ZouKH O'MalleyAJ MauriL. 2007. Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models. Circulation 115:654\u2013657.","journal-title":"Circulation"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jviromet.2004.11.020","article-title":"Validation of IgG-sandwich and IgM-capture ELISA for the detection of antibody to Rift Valley fever virus in humans","volume":"124","author":"Paweska JT","year":"2005","unstructured":"PaweskaJT BurtFJ SwanepoelR. 2005. Validation of IgG-sandwich and IgM-capture ELISA for the detection of antibody to Rift Valley fever virus in humans. J. Virol. Methods 124:173\u2013181.","journal-title":"J. Virol. Methods"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","unstructured":"SiddiquiMA\nKhanMA\nAhmedSS\nAnwarKS\nAkhtaruzzamanSM\nSalamMA. 2012. Recent outbreak of cutaneous anthrax in Bangladesh: clinico-demographic profile and treatment outcome of cases attended at Rajshahi Medical College Hospital. BMC Res. Notes 5:464. doi:10.1186\/1756-0500-5-464.","DOI":"10.1186\/1756-0500-5-464"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"703","DOI":"10.4269\/ajtmh.2012.11-0234","article-title":"Anthrax outbreaks in Bangladesh, 2009\u20132010","volume":"86","author":"Chakraborty A","year":"2012","unstructured":"ChakrabortyA KhanSU HasnatMA ParveenS IslamMS MikolonA ChakrabortyRK AhmedBN AraK HaiderN ZakiSR HoffmasterAR RahmanM LubySP HossainMJ. 2012. Anthrax outbreaks in Bangladesh, 2009\u20132010. Am. J. Trop. Med. Hyg. 86:703\u2013710.","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.3201\/eid1808.111343","article-title":"Molecular epidemiologic investigation of an anthrax outbreak among heroin users, Europe","volume":"18","author":"Price EP","year":"2012","unstructured":"PriceEP SeymourML SarovichDS LathamJ WolkenSR MasonJ VincentG DreesKP Beckstrom-SternbergSM PhillippyAM KorenS OkinakaRT ChungWK SchuppJM WagnerDM VipondR FosterJT BergmanNH BuransJ PearsonT BrooksT KeimP. 2012. Molecular epidemiologic investigation of an anthrax outbreak among heroin users, Europe. Emerg. Infect. Dis. 18:1307\u20131313.","journal-title":"Emerg. Infect. Dis."},{"key":"e_1_3_2_28_2","volume-title":"Anthrax in animal and humans","author":"WHO","year":"2008","unstructured":"WHO. 2008. Anthrax in animal and humans. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.mam.2009.06.002","article-title":"Anthrax toxins: a weapon to systematically dismantle the host immune defenses","volume":"30","author":"Tournier JN","year":"2009","unstructured":"TournierJN Rossi PaccaniS Quesnel-HellmannA BaldariCT. 2009. Anthrax toxins: a weapon to systematically dismantle the host immune defenses. Mol. Aspects Med. 30:456\u2013466.","journal-title":"Mol. Aspects Med."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00598-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00598-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:48:40Z","timestamp":1627591720000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00598-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["10.1128\/CVI.00598-12"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00598-12","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"2012-10-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-12-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-01-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}